Preischemic iloprost application for improvement of graft preservation: which route is superior in experimental pig lung transplantation: inhaled or intravenous?
BACKGROUND
Optimal allograft protection is essential in lung transplantation to reduce postoperative organ dysfunction. Although intravenous prostanoids are routinely used to ameliorate reperfusion injury, the latest evidence suggests a similar efficacy of inhaled prostacyclin. Therefore, we compared donor lung-pretreatment using inhaled lioprost (Ventavis) with the commonly used intravenous technique.


METHODS
Five pig lungs were each preserved with Perfadex and stored for 27 hours without (group 1) or with (group-2, 100 prior aerosolized of iloprost were (group 3) or iloprost (IV). Following left lung transplantation, hemodynamics, Po(2)/F(i)o(2), compliance, and wet-to-dry ratio were monitored for 6 hours and compared to sham controls using ANOVA analysis with repeated measures.


RESULTS
The mortality was 100% in group 3. All other animals survived (P < .001). Dynamic compliance and PVR were superior in the endobronchially pretreated iloprost group as compared with untreated organs (P < .05), whereas oxygenation was comparable overall W/D-ratio revealed significantly lower lung water in group 2 (P = .027) compared with group 3.


CONCLUSIONS
Preischemic alveolar deposition of iloprost is superior to IV pretreatment as reflected by significantly improved allograft function. This strategy offers technique to optimize pulmonary preservation.
Wittwer
T
T
Department of Cardiothoracic Surgery, University of Cologne, Kerpener Strasse 62, Cologne 50924, Germany. Th.Wittwer-md@t-online.de
Franke
U F
UF
Sandhaus
T
T
Thiene
M
M
Groetzner
J
J
Strauch
J T
JT
Wippermann
J
J
Ochs
M
M
Muehlfeld
C
C
D000280:Administration, Inhalation; D000818:Animals; D006085:Graft Survival / Q000187:drug effects*; D016285:Iloprost / Q000008:administration & dosage / Q000627:therapeutic use*; D007275:Injections, Intravenous; D016040:Lung Transplantation / Q000009:adverse effects / Q000502:physiology*; D023421:Models, Animal; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D015427:Reperfusion Injury / Q000517:prevention & control*; D013552:Swine
D010975:Platelet Aggregation Inhibitors; D016285:Iloprost